Read an endotoxin result with its assay format, units, reporting boundary and sample-suitability information. Endotoxin testing is a separate analytical question from a culture-based no-growth result.
Keep the analytical targets separate
Bacterial endotoxin assays address lipopolysaccharide-related material. Culture-based tests address microbial growth under their conditions. One result should not be substituted for the other, and neither is a chromatographic peptide-purity measurement.FDA endotoxin background (opens in a new tab)FDA endotoxin-testing guidance (opens in a new tab)
Endotoxin results use endotoxin units, often expressed per volume or mass. Preserve the denominator. A less-than result such as the supplied water report’s <0.25 EU/mL is a reported bound, not an exact measurement of zero.FDA endotoxin-testing guidance (opens in a new tab)Water report (PDF) (opens in a new tab)
Recognise the readout
| Format | Reported signal or outcome |
|---|---|
| LAL gel-clot | Clot endpoint under stated conditions |
| LAL turbidimetric | Change in turbidity |
| LAL chromogenic | Colour-producing reaction |
| Recombinant factor C (rFC) | Factor-C-based reaction with a fluorescent readout in the cited documentation |
The format name alone does not establish sensitivity or suitability for a peptide sample. Read the calibration, sample basis and method qualifications. Do not infer a particular reagent format from a certificate that merely says “endotoxin”.FDA endotoxin-testing guidance (opens in a new tab)Lonza — LAL assay principles and formats (opens in a new tab)Lonza — PyroGene recombinant factor C assay documentation (opens in a new tab)
Ask about interference and reporting limits
A sample can interfere with an assay response. Suitability evidence should address the material actually tested, including the relevant dilution and recovery checks. A satisfactory check at one stage does not by itself establish suitability after a different holding period or sample condition.FDA endotoxin-testing guidance (opens in a new tab)
Keep detection or quantification boundaries separate from the acceptance limit. If the report gives only a result below its reporting boundary, compare that boundary with the actual criterion; do not invent a more sensitive measurement.FDA endotoxin-testing guidance (opens in a new tab)
A focused enquiry asks for the assay format, result units, tested sample stage, reporting boundary and suitability evidence. If any point is missing, record the gap without diagnosing a cause from the number alone.FDA endotoxin-testing guidance (opens in a new tab)
Sources and further detail
- FDA — Endotoxin technical guide (opens in a new tab)
Historical guide used only for the analytical target; older assay-availability statements are not adopted.
- FDA — Endotoxin-testing guidance, edition 2 (2026) (opens in a new tab)
Reference standards, sample suitability and analytical reporting; no acceptance limit assigned to a Novum product.
- Lonza — LAL assay principles and formats (opens in a new tab)
Official gel-clot, kinetic turbidimetric and kinetic chromogenic explanations. Product sensitivity ranges and vendor superiority claims are not adopted.
- Lonza — PyroGene recombinant factor C assay documentation (opens in a new tab)
Official detection-principle document: factor C activation and fluorogenic readout. No kit operating protocol reproduced.
- Supplied bacteriostatic water 3 mL certificate (opens in a new tab)
MA-WFI-0047, revision 01; task TJK2ADP; lot WFI-47-ADP. TOC sample basis and sterility-test timing remain unresolved; see the article. The cited PDF was re-read on 3 October 2026 to check this transcription; its issuer and findings were not independently authenticated.
Revised from the existing source dossier on 3 October 2026. Supplied-report values are document transcriptions, not independent authentication or new measurements. Source notes identify the scope of each reference; this article has not undergone independent scientific peer review.